28.06.2010 • News • Big Pharma • Merck & Co. • Pfizer

Big Pharma Stocks Could Rally in the Next Year

Wall Street appears to be overly pessimistic about large pharmaceutical companies, and some of the stocks could rally 30% over the next year, according to a cover story in the June 28th edition of Barron's. Some of the best value lies in Merck & Co, Pfizer, Sanofi-Aventis, Novartis and Roche, according to the article in the weekly financial publication. Bristol-Myers Squibb, Eli Lilly and Astrazeneca do not look as attractive as some of their peers, the Barron's article said.

(6/28/2010)

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.